Keybanc analyst Paul Knight maintains Harvard Bioscience (NASDAQ:HBIO) with a Overweight and lowers the price target from $10 to $7.
Roku Stock Down 22% Despite ‘Almost Perfect Quarter’: Analyst Expects Stock To Be ‘Range-Bound Until Platform Growth Returns’
Roku stock slid on lower early trading on Feb. 16 due to a cautionary statement on 2024 spending deceleration in the entertainment industry. Despite a Q4 earnings beat, analysts have mixed opinions on the company's future growth.
